Acorah Software Products - Accounts Production 16.1.300 false true true 31 December 2022 1 January 2022 false 1 January 2023 31 December 2023 31 December 2023 09905584 Mr Max Baumann iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 09905584 2022-12-31 09905584 2023-12-31 09905584 2023-01-01 2023-12-31 09905584 frs-core:CurrentFinancialInstruments 2023-12-31 09905584 frs-core:Non-currentFinancialInstruments 2023-12-31 09905584 frs-core:CopyrightsPatentsTrademarksServiceOperatingRights 2023-12-31 09905584 frs-core:CopyrightsPatentsTrademarksServiceOperatingRights 2023-01-01 2023-12-31 09905584 frs-core:CopyrightsPatentsTrademarksServiceOperatingRights 2022-12-31 09905584 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-01-01 2023-12-31 09905584 frs-core:OtherResidualIntangibleAssets 2023-12-31 09905584 frs-core:OtherResidualIntangibleAssets 2023-01-01 2023-12-31 09905584 frs-core:OtherResidualIntangibleAssets 2022-12-31 09905584 frs-core:SharePremium 2023-12-31 09905584 frs-core:ShareCapital 2023-12-31 09905584 frs-core:RetainedEarningsAccumulatedLosses 2023-12-31 09905584 frs-bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 09905584 frs-bus:FilletedAccounts 2023-01-01 2023-12-31 09905584 frs-bus:SmallEntities 2023-01-01 2023-12-31 09905584 frs-bus:AuditExemptWithAccountantsReport 2023-01-01 2023-12-31 09905584 frs-bus:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 09905584 frs-bus:Director1 2023-01-01 2023-12-31 09905584 frs-core:Non-currentFinancialInstruments 1 2023-12-31 09905584 frs-countries:EnglandWales 2023-01-01 2023-12-31 09905584 2021-12-31 09905584 2022-12-31 09905584 2022-01-01 2022-12-31 09905584 frs-core:CurrentFinancialInstruments 2022-12-31 09905584 frs-core:Non-currentFinancialInstruments 2022-12-31 09905584 frs-core:SharePremium 2022-12-31 09905584 frs-core:ShareCapital 2022-12-31 09905584 frs-core:RetainedEarningsAccumulatedLosses 2022-12-31 09905584 frs-core:Non-currentFinancialInstruments 1 2022-12-31
Registered number: 09905584
SHARPVIEW OPHTHALMOLOGY LIMITED
Unaudited Financial Statements
For The Year Ended 31 December 2023
Anderson Ross Accounting & Tax Ltd
G-05 Davenport House
16 Pepper Street
London
E14 9RP
Contents
Page
Accountants' Report 1
Balance Sheet 2—3
Notes to the Financial Statements 4—6
Page 1
Accountants' Report
Report to the directors on the preparation of the unaudited statutory accounts of SHARPVIEW OPHTHALMOLOGY LIMITED for the year ended 31 December 2023
To assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of SHARPVIEW OPHTHALMOLOGY LIMITED which comprise the Profit and Loss Account, the Balance Sheet and the related notes, from the company’s accounting records and from information and explanations you have given us.
As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at http://www.accaglobal.com/en/member/professional-standards/rules-standards/acca-rulebook.html.
This report is made to the directors of SHARPVIEW OPHTHALMOLOGY LIMITED , as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of SHARPVIEW OPHTHALMOLOGY LIMITED and state those matters that we have agreed to state to the directors of SHARPVIEW OPHTHALMOLOGY LIMITED , as a body, in this report in accordance with the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/content/dam/ACCA_Global/Technical/fact/technical-factsheet-163.pdf. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than SHARPVIEW OPHTHALMOLOGY LIMITED and its directors as a body for our work or for this report.
It is your duty to ensure that SHARPVIEW OPHTHALMOLOGY LIMITED has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit or loss of SHARPVIEW OPHTHALMOLOGY LIMITED . You consider that SHARPVIEW OPHTHALMOLOGY LIMITED is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the accounts of SHARPVIEW OPHTHALMOLOGY LIMITED . For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements.
Signed
Anderson Ross Accounting & Tax Ltd
29 January 2025
Anderson Ross Accounting & Tax Ltd
G-05 Davenport House
16 Pepper Street
London
E14 9RP
Page 1
Page 2
Balance Sheet
Registered number: 09905584
2023 2022
Notes £ £ £ £
FIXED ASSETS
Intangible Assets 4 761,725 897,226
761,725 897,226
CURRENT ASSETS
Stocks 5 125,512 -
Debtors 6 182,528 96,542
Cash at bank and in hand 386,821 980,209
694,861 1,076,751
Creditors: Amounts Falling Due Within One Year 7 (4,918,266 ) (415,380 )
NET CURRENT ASSETS (LIABILITIES) (4,223,405 ) 661,371
TOTAL ASSETS LESS CURRENT LIABILITIES (3,461,680 ) 1,558,597
Creditors: Amounts Falling Due After More Than One Year 8 - (3,212,367 )
NET LIABILITIES (3,461,680 ) (1,653,770 )
CAPITAL AND RESERVES
Called up share capital 9 10 10
Share premium account 1,200,090 1,200,090
Profit and Loss Account (4,661,780 ) (2,853,870 )
SHAREHOLDERS' FUNDS (3,461,680) (1,653,770)
Page 2
Page 3
For the year ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr Max Baumann
Director
29 January 2025
The notes on pages 4 to 6 form part of these financial statements.
Page 3
Page 4
Notes to the Financial Statements
1. General Information
SHARPVIEW OPHTHALMOLOGY LIMITED is a private company, limited by shares, incorporated in England & Wales, registered number 09905584 . The registered office is G-05 Davenport House, 16 Pepper Street, London, , E14 9RP.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Going Concern Disclosure
The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern.
2.3. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
2.4. Intangible Fixed Assets and Amortisation - Other Intangible
Other intangible assets are website development costs. It is amortised to profit and loss account over its estimated economic life of 10 years.
2.5. Intangible Fixed Assets and Amortisation - Intellectual Property
Intellectual property assets are proprietary technology and website development costs. It is amortised to the profit and loss account over its estimated economic life of 9 years.
2.6. Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
2.7. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
3. Average Number of Employees
Average number of employees, including directors, during the year was:
2023 2022
Office and administration 5 5
5 5
Page 4
Page 5
4. Intangible Assets
Other Intellectual Property Total
£ £ £
Cost
As at 1 January 2023 22,775 1,199,000 1,221,775
As at 31 December 2023 22,775 1,199,000 1,221,775
Amortisation
As at 1 January 2023 2,550 321,999 324,549
Provided during the period 2,278 133,223 135,501
As at 31 December 2023 4,828 455,222 460,050
Net Book Value
As at 31 December 2023 17,947 743,778 761,725
As at 1 January 2023 20,225 877,001 897,226
5. Stocks
2023 2022
£ £
Stock 125,512 -
The sales for the years 2021-2023 have been taken from the stock at the beginning of 2021
6. Debtors
2023 2022
£ £
Due within one year
Trade debtors 132,427 64,121
Prepayments and accrued income 20,616 19,400
Other debtors 27,405 12,160
VAT 715 861
Amounts owed by subsidiaries 1,365 -
182,528 96,542
7. Creditors: Amounts Falling Due Within One Year
2023 2022
£ £
Trade creditors 1,366,342 413,430
Other loans 3,548,724 -
Accruals and deferred income 3,200 1,950
4,918,266 415,380
Page 5
Page 6
8. Creditors: Amounts Falling Due After More Than One Year
2023 2022
£ £
Loan - 3,212,367
9. Share Capital
2023 2022
£ £
Allotted, Called up and fully paid 10 10
Page 6